Initial data from the first cohort of 10 participants demonstrates excellent safety profile for CELZ-201-DDT stem cell therapy, with no serious adverse events reported in degenerative disc disease treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.